Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Milia

Also known as: milium, milial cysts, milk spots

Milia are tiny, benign cysts containing keratin, a skin protein. They usually appear as firm white or yellowish bumps, especially around the eyes and cheeks. Some arise spontaneously; others develop as skin heals after injury or another skin disorder.

In plain English — Milia are little cysts filled with a skin protein called keratin. Many can be left alone, although a clinician can discuss removal when they are persistent or bothersome. A bump that has not been clearly identified should be assessed before anyone tries to remove it.

Evidence status

Limited

Established clinical entity; limited comparative treatment evidence. Clinical references describe recognition, natural history and established removal options. Direct procedural studies include small case series, with limited evidence to compare long-term clearance and harms between treatments.

What milia are, and the types encountered#

Milium is singular; miliais plural. Typical lesions are firm, rounded, pearly white or yellowish bumps, often about 1–2 mm across. The surrounding skin is commonly normal. Eyelids and cheeks are frequent sites.[1, 2, 3]

The main distinction is between spontaneous primary milia and secondary milia arising in a site affected by injury, a skin disorder or a medicine. Neonatal lesions commonly settle spontaneously; lesions in older children and adults can persist.[2, 3][1, 2, 3]

Less common patterns include milia en plaque, where multiple cysts occur in a raised or inflamed patch, and multiple eruptive milia, where numerous lesions appear over weeks to months. Recognising that distribution helps direct assessment.[2, 3]

The subject here is the cysts and their clinical context. Comedones explains blocked follicles; extraction discusses that procedure rather than every small facial bump.

Use of milia in aesthetic practice#

A skincare consultation can establish what concerns the person, how long the bumps have been present and whether they followed a procedure, rash or medicine. Reassurance is useful when the diagnosis is established: observation is a recognised management choice.[1, 2, 3]

For persistent lesions, the discussion can move to assessment by someone competent to diagnose and manage the particular presentation. Removal, prescription treatment and ordinary cosmetic support are separate decisions; the condition’s name does not supply a procedure protocol. This is a clinical-scope distinction, not a statement of UK-wide licensing law.[1, 2, 8]i

Contraindications and cautions#

Do not proceed with cosmetic destruction or skin-opening removal of an undiagnosed lesion. Where tissue examination may be required, assessment comes first.[2, 3, 8]i

Blistering, damaged surrounding skin or an unusual plaque needs attention to the underlying disorder. Near-eye lesions also require site-appropriate assessment and procedural precautions.[2, 3, 8]i

Topical retinoid medicines must be avoided during pregnancy and when planning pregnancy. Their selection for a particular presentation belongs to the prescribing clinician; cosmetic retinol is covered separately in retinoids.[6]

Clinical uses and the evidence behind them#

Observation and established clinical management

PCDS guidance supports leaving uncomplicated milia untreated and recognises spontaneous disappearance. For adults seeking removal, it describes evacuation and selected destructive procedures. These are expert clinical recommendations, not comparative trial estimates.[1, 2, 3]

Dermatology references also describe topical retinoids for more extensive presentations. The choice depends on diagnosis, distribution and suitability for the medicine.[1, 2, 3]

Procedural reports

A 2010 uncontrolled series treated four people aged 12–50 with several milia variants using CO2 laser. All were reported to improve markedly, with follow-up of 12–36 months. The accessible abstract omits anatomical sites, phototypes and funding or conflict declarations; those details cannot be supplied from the authors’ hospital affiliation.[4]

The report provides direct clinical experience relevant to specialist discussion. The broader procedure and its precautions are covered in laser resurfacing.

Selecting care for milia#

Selection starts with confidence in the lesion’s identity, then the person’s priorities. A small number of stable, recognised cysts that are not troubling them can reasonably be observed. A widespread eruption or a cluster on abnormal skin shifts the discussion towards diagnosis and cause.[1, 2, 8]i

Ask about preceding blistering, injury and procedures, as well as current medicines. The distinction between primary and secondary lesions makes that history clinically relevant. For removal, discuss the proposed method’s risks and the particular site’s needs before committing to treatment.[1, 2, 8]i[2, 3]

Adverse effects and their management#

Adverse effects depend on the intervention. Cryotherapy, for example, can cause pain, swelling and blisters; recognised complications include infection, lasting pigment loss and scars. Those are general cryotherapy risks, not a measured complication rate for milia.[8]

Painful, hot, swollen skin after a procedure warrants urgent medical assessment. Redness can be less obvious on brown or black skin. Serious associated symptoms such as confusion, faintness or fast breathing warrant emergency help.[7]

The treating clinician should provide the instructions and contact route for the actual intervention; no removal or wound-care regimen is prescribed here.

Referral and scope boundaries#

Clinical assessment is appropriate when lesion identity is uncertain or when the appearance is atypical. The differential includes syringomas, xanthelasma, comedones and other cysts; an occasional lesion needs biopsy.[2]

Numerous new lesions, milia within an abnormal plaque, recurrent blistering, or a striking early-onset familial pattern deserve medical review. The relevant question is whether the cysts are isolated or part of another disorder. Rare inherited associations are a reason to assess the whole presentation, not to infer a syndrome from a few ordinary facial milia.[2, 3, 8]i

For secondary milia following a prescribed treatment or procedure, communicate with that clinician about the history before changing the medical plan. This is an assessment principle drawn from the documented associations.[2, 3]

Mechanism of action#

As a condition, the relevant mechanism is cyst formation. Histology shows a small cavity containing keratin with a lining of epithelial cells.[3]

The structures involved can vary. Human light and electron microscopy of secondary milia found connections to eccrine sweat ducts in many post-blistering specimens. This was tissue research involving 10 patients overall, not an ingredient experiment; it supports an anatomical explanation for some secondary lesions. The original abstract omits body sites, ages and funding.[5]

Commonly misstated claims#

Cyst contents

Claim heard:“Milia are little deposits of fat”

Literature finding: The defining histological material is keratin inside an epithelial-lined cyst. Calling this a deposit of fat changes the tissue being described.[3]

Supported statement: Milia are keratin-containing cysts.

Product exposure and causation

Claim heard:“Rich eye creams are proven to cause milia”

Literature finding: No controlled human study establishing that rich eye creams as a class cause milia was identified. Advice about individual products and reports involving healing procedural wounds do not settle that broad claim.[no source found]

Supported statement:A person’s product history may be relevant, but class-wide causation on intact periocular skin remains unverified in the evidence reviewed here.

Laser case-series follow-up

Claim heard:“Laser removes milia permanently and has no side effects”

Literature finding: The four-patient CO2 report recorded no recurrence or noticeable side effects during its follow-up. That is a favourable result in four selected patients, not a general clearance percentage or a study capable of excluding uncommon complications.[4]i

Supported statement: CO2 laser has a positive small case series; the result does not establish guaranteed permanent clearance or universal safety.

Areas of remaining uncertainty#

  • Choosing between procedures.The retrieved clinical references describe several options, while the direct laser report is uncontrolled. Treatment comparisons therefore need to account for the individual’s site and priorities rather than assume a proven ranking.[1, 2, 3][4]i
  • Time to spontaneous resolution. Adult lesions can persist and references describe variable courses. A consultation cannot give a precise disappearance date for a particular cyst.[1, 2, 3]
  • Outcomes across skin tones. The accessible laser abstract does not report phototypes. Its outcome should not supply an individual pigment-risk estimate for a different population.[4]

Frequently asked questions#

Which details are helpful before a clinical appointment?

The timing, distribution and any preceding rash, injury, procedure or medicine help distinguish spontaneous lesions from secondary milia.[2, 3]

Do uncomplicated milia always need treatment?

No. Observation is a recognised choice when the diagnosis is established and the person is comfortable with their appearance.[1, 2, 3]

What is the next step for a cluster on an inflamed patch?

Arrange clinical assessment of the pattern and surrounding skin. Milia en plaque is one recognised possibility, and the underlying diagnosis guides management.[2, 3]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Cunliffe T. Milia. Primary Care Dermatology Society. Updated 12 June 2023. Accessed 16 September 2026.Tier 4Supports: Clinical morphology, spontaneous resolution, observation and recognised procedural options; skin-injury associations.Funding / interest: PCDS professional reference; site acknowledges pharmaceutical sponsors and states they had no involvement in website content. No article-specific funding declaration located.
  2. Gupta M, Oakley A. Milium. DermNet. 2009. Accessed 16 September 2026.Tier 4Supports: Types, locations, differential diagnosis, occasional biopsy, natural history and treatment overview.Funding / interest: Expert clinical reference; no article-specific sponsorship or conflict statement located. The website carries advertising.
  3. Berk DR, Bayliss SJ. Milia: a review and classification. J Am Acad Dermatol. 2008;59(6):1050–1063. doi:10.1016/j.jaad.2008.07.034. PMID:18819726.Tier 4Supports: Full original article retrieved; histology, primary/secondary classification, adult persistence, unusual patterns and treatment discussion. No systematic search or risk-of-bias method stated.Funding / interest: Original article states no funding sources and no conflicts of interest.
  4. del Pozo J, Castiñeiras I, Fernández-Jorge B. Variants of milia successfully treated with CO(2) laser vaporization. J Cosmet Laser Ther. 2010;12(4):191–194. doi:10.3109/14764172.2010.502455. PMID:20590368.Tier 3Supports: Original abstract; uncontrolled four-patient series, ages 12–50, several milia variants, follow-up 12–36 months. Marked improvement without reported recurrence or noticeable side effects. Anatomical sites and phototypes not stated in abstract.Funding / interest: Funding and conflicts unavailable in retrieved abstract; manufacturer involvement can neither be confirmed nor excluded.
  5. Tsuji T, Sugai T, Suzuki S. The mode of growth of eccrine duct milia. J Invest Dermatol. 1975;65(4):388–393. doi:10.1111/1523-1747.ep12607643. PMID:1176789.Tier 3Supports: Original human microscopy abstract retrieved via Europe PMC; 10 patients overall, including 69 post-blistering milia from eight patients and four control milia from two. Sweat-duct connections identified in 52 of 69 post-blistering specimens; descriptive histology, not a treatment trial.Funding / interest: Funding and conflicts not stated in retrieved abstract. Full original article inaccessible during retrieval.
  6. MHRA. Oral retinoid medicines: revised and simplified pregnancy prevention educational materials for healthcare professionals and women. Drug Safety Update. 19 June 2019. Section: Teratogenic risk with topical retinoids.Tier 1Supports: Topical retinoid medicines contraindicated during pregnancy as a precaution and avoided when planning pregnancy. Only that topical subsection is used.Funding / interest: MHRA official medicines-safety communication, not a milia efficacy study or procedural-licensing instrument.
  7. NHS. Cellulitis. Reviewed 18 April 2024. Accessed 16 September 2026.Tier 4Supports: Painful, hot, swollen skin requires urgent assessment; serious systemic features require emergency care. Redness may be less visible in brown or black skin.Funding / interest: NHS public information; no article-specific commercial funding identified.
  8. Oakley A, Nguyen JK. Cryotherapy. DermNet. Updated August 2022. Accessed 16 September 2026.Tier 4Supports: Procedure-specific cautions for undiagnosed lesions and lesions needing pathology; pain, blistering, infection, pigment change and scarring. Not milia-specific incidence data.Funding / interest: Expert clinical reference; no article-specific sponsorship or conflict statement located. The website carries advertising.